학술논문
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study
Document Type
Article
Author
Dimopoulos, M.A.; Hungria, V.T.M.; Radinoff, A.; Delimpasi, S.; Mikala, G.; Masszi, T.; Li, J.; Capra, M.; Maiolino, A.; Pappa, V.; Chraniuk, D.; Osipov, I.; Leleu, X.; Low, M.; Matsumoto, M.; Sule, N.; Li, M.; Roy-Ghanta, S.; Opalinska, J.; McKeown, A.; He, W.; Bright, S.; Currie, B.; Perera, S.; Boyle, J.; Weisel, K.
Source
In: The Lancet Haematology . (The Lancet Haematology, October 2023, 10(10):e801-e812)
Subject
Language
English
ISSN
23523026